Georg M N Behrens Selected Research

COVID-19

10/2022	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
1/2022	SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination.
1/2022	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
1/2022	Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
1/2022	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern.
1/2022	Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade.
12/2021	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination.
10/2021	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination.
8/2021	Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
1/2021	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Georg M N Behrens Research Topics

Disease

16	COVID-19 10/2022 - 08/2020
11	Infections 01/2022 - 02/2006
5	Inflammation (Inflammations) 12/2012 - 09/2008
4	HIV Infections (HIV Infection) 10/2020 - 04/2003
3	Neoplasms (Cancer) 01/2022 - 05/2004
3	Lipodystrophy 09/2005 - 11/2002
2	Convalescence 01/2022 - 01/2021
2	Chickenpox 12/2017 - 12/2016
2	Measles 12/2017 - 12/2016
2	Rubella (German Measles) 12/2017 - 12/2016
2	Virus Diseases (Viral Diseases) 05/2016 - 06/2004
2	Eosinophilia 12/2012 - 05/2010
2	Mitochondrial Diseases (Mitochondrial Disease) 10/2012 - 01/2010
2	Asthma (Bronchial Asthma) 05/2010 - 09/2008
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2005 - 01/2003
2	Insulin Resistance 09/2005 - 11/2002
1	Anxiety Disorders (Anxiety Disorder) 01/2022
1	Hepatitis 01/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Skin Neoplasms (Skin Cancer) 01/2022
1	Chronic Renal Insufficiency 08/2021
1	Vesicular Stomatitis 01/2021
1	Hypophosphatemia 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Reinfection 01/2021
1	Severe Acute Respiratory Syndrome 12/2020
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2020
1	Syphilis 12/2018
1	Tuberculosis (Tuberculoses) 01/2018
1	Hepatitis A (Hepatitis, Infectious) 08/2017
1	Tetanus 04/2017
1	Diphtheria 04/2017
1	Mumps 12/2016
1	Hepatitis B 05/2016
1	Starvation 01/2014
1	Hepatocellular Carcinoma (Hepatoma) 01/2014
1	Myocardial Infarction 10/2011
1	Respiratory Hypersensitivity 05/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2010

Drug/Important Bio-Agent (IBA)

10	AntibodiesIBA 10/2022 - 08/2017
8	Immunoglobulin G (IgG)IBA 01/2022 - 05/2010
7	AntigensIBA 08/2017 - 06/2004
6	VaccinesIBA 01/2022 - 03/2013
4	Antiviral Agents (Antivirals)IBA 01/2022 - 02/2006
3	bamlanivimabIBA 01/2022 - 01/2021
3	AllergensIBA 12/2012 - 05/2010
3	LipidsIBA 10/2012 - 06/2005
2	Neutralizing AntibodiesIBA 01/2022 - 12/2021
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2017
2	BNT162 VaccineIBA 10/2021 - 01/2021
2	EnzymesIBA 12/2020 - 05/2016
2	Viral AntigensIBA 10/2017 - 11/2011
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2012 - 02/2006
1	cilgavimabIBA 10/2022
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 10/2022
1	sotrovimabIBA 10/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 10/2022
1	COVID-19 VaccinesIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Antitubercular AgentsIBA 01/2022
1	Anti-Anxiety Agents (Anxiolytics)IBA 01/2022
1	Monoclonal AntibodiesIBA 10/2021
1	InterferonsIBA 01/2021
1	Caspase 3 (Caspase-3)IBA 01/2021
1	SARS-CoV-2 spike proteinIBA 01/2021
1	Phosphates (Orthophosphate)IBA 01/2021
1	Tenofovir (Viread)FDA Link 01/2021
1	ImmunosorbentsIBA 12/2020
1	hemoglobin ASIBA 10/2020
1	Immunoglobulin A (IgA)IBA 08/2020
1	Adenosine Triphosphate (ATP)IBA 12/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2018
1	Interferon-gamma (Interferon, gamma)IBA 01/2018
1	BilirubinIBA 05/2016
1	Alkaline PhosphataseIBA 05/2016
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 05/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2014
1	Pharmaceutical PreparationsIBA 01/2014
1	salinomycinIBA 01/2014
1	EpitopesIBA 03/2013
1	OvalbuminIBA 12/2012
1	Toll-Like Receptor AgonistsIBA 12/2012
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 12/2012
1	Peptides (Polypeptides)IBA 12/2012
1	abacavir (Ziagen)FDA Link 10/2011
1	CytokinesIBA 05/2010
1	Antigen-Antibody Complex (Immune Complex)IBA 05/2010
1	Mitochondrial DNA (mtDNA)IBA 01/2010
1	Reverse Transcriptase InhibitorsIBA 01/2010
1	NucleosidesIBA 01/2010
1	OligonucleotidesIBA 09/2009
1	Stavudine (Zerit)FDA LinkGeneric 01/2009
1	Immunoglobulin E (IgE)IBA 09/2008

Therapy/Procedure

13	Therapeutics 10/2022 - 04/2003
4	Highly Active Antiretroviral Therapy (HAART) 06/2005 - 11/2002
2	Immunotherapy 01/2021 - 05/2004
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2022
1	Aftercare (After-Treatment) 12/2018
1	Mucosal Administration 12/2012